Skip to content

A study on the mechanism by which the Qi-Boosting, Stasis-Resolving and Detoxifying Formula blocks the "anti-inflammatory - cancer" transformation of CAG based on the regulation of cellular senescence by the JAK-STAT signaling pathway

A study on the mechanism by which the Qi-Boosting, Stasis-Resolving and Detoxifying Formula blocks the "anti-inflammatory - cancer" transformation of CAG based on the regulation of cellular senescence by the JAK-STAT signaling pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105887
Enrollment
Unknown
Registered
2025-07-14
Start date
2025-07-20
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic atrophic gastritis

Interventions

Chronic atrophic gastritis group:The chronic atrophic gastritis group was treated with the YIQIHUAYUJIEDU formula. The formula consisted of: Astragalus membranaceus 30g, Codonopsis pilosula 15g, Atrac

Sponsors

Beijing University of Chinese Medicine Shenzhen Hospital (Longgang)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the diagnostic criteria for gastric precancerous diseases (confirmed by electronic gastroscopy and histopathological examination as atrophy, with or without intestinal metaplasia, with or without mild to moderate dysplasia) or the diagnostic criteria for CSG (chronic superficial gastritis), and are diagnosed with spleen deficiency syndrome in traditional Chinese medicine (TCM); 2. Age between 18 and 65 years; 3. No intake of relevant medications within one week; 4. Able to communicate normally and sign the informed consent form; Only those who meet all the above criteria can be included in the study.

Exclusion criteria

Exclusion criteria: (1) Patients with organic gastrointestinal diseases, including peptic ulcers, type A gastritis, gastrointestinal tumors, or gastrointestinal bleeding; (2) Patients with severe comorbidities affecting the heart, brain, kidneys, liver, or coagulation function; (3) Patients with a history of gastric surgery; (4) Patients unable to cooperate with biopsy collection; (5) Pregnant or lactating women, as well as individuals with severe mental illness who are unwilling to comply with the study. Patients meeting any of the above criteria were excluded from the study.

Design outcomes

Primary

MeasureTime frame
Pathological score of gastric mucosa;The results of gastric endoscopy examination;Transcriptomics of gastric mucosal tissue;Metagenomics of gastric mucosal tissue;The expression of p-JAK2 protein and JAK2 gene in gastric mucosal tissue;The expression of p-STAT3 protein and STAT3 gene in gastric mucosal tissue;The expression of P53 protein and genes in gastric mucosal tissue;The expression of P21 protein and genes in gastric mucosal tissue;

Secondary

MeasureTime frame
Liver function;renal function;

Countries

China

Contacts

Public ContactShuni Chen

Beijing University of Chinese Medicine Shenzhen Hospital (Longgang)

247721840@qq.com+86 137 1704 0580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026